Progressive Supranuclear Palsy(PSP)
10
4
5
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
0%
0 trials in Phase 3/4
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Clinical Trials (10)
Tracking and Predicting How Brain Damage Spreads in Neurodegenerative Diseases
The Progressive Supranuclear Palsy Clinical Trial Platform
Digital Health Technologies for Progressive Supranuclear Palsy and Dementia With Lewy Bodies
Study on Artificial Intelligence-Based Facial and Speech-Related Patterns in Parkinson's Disease and Their Digital Biomarkers
UPenn Observational Research Repository on Neurodegenerative Disease
The CurePSP Genetics Program
Neuroinflammation in FTLD
Collection of Digital Parameters From Parts of the Neurological Examination Using an Eye Tracker
AI-Enhanced Optimization of Acute Levodopa Challenge Test
Parkinson Atypical Rating of Oculometric Patterns Evaluated Routinely